Preimplantation Genetic Testing Market To Reach $1.28 Billion By 2030

Preimplantation Genetic Testing Market Growth & Trends

The global preimplantation genetic testing market size is expected to reach USD 1.28 billion by 2030, registering a CAGR of 7.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Recent technological advancements in testing have changed the current practice of prenatal screening and early detection of chromosomal abnormalities in an embryo. Moreover, the introduction of novel technologies such as NGS, PCR, and FISH is expected to drive market growth over the forecast period.

Growing awareness about genetic diseases and novel techniques for the detection of chromosomal abnormalities and embryo screening for successful IVF holds growth prospects for this vertical over the forecast period. Key market players and service providers such as COOPER SURGICAL, INC. are running awareness campaigns to promote an increased understanding of the diseases and screening of these diseases at the early stages. Such favorable initiatives are expected to increase the demand for PDT in IVF procedures globally.

The increasing adoption of in vitro fertilization (IVF) technique consequently upsurges the utilization of preimplantation genetic testing (PGT). These techniques are advantageous in allowing the development of a healthy fetus and preventing the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

Moreover, the increased risk of genetic disease in newborns and complications associated with IVF procedures push healthcare providers to recommend PGT. For instance, according to the CDC, in the U.S., about 6,000 babies are born with Down syndrome each year. It is the most common chromosomal condition diagnosed in newborns in the country. Moreover, the high risk associated with aged pregnancy further increases the adoption of PGT worldwide.

Key companies are involved in developing novel methods and solutions to carry out preimplantation genetic diagnosis and screening. To maintain their significant share in the revenue in the coming years, these participants are undertaking strategic initiatives. The strategic undertakings include regional expansion, collaborative development, and new product developments.

For instance, in October 2022, Ovation Fertility and Genomic Prediction partnered to expand genetic testing services by using the LifeView PGT platform for PFT. Moreover, in April 2022, Clevergene received PCPNDT for prenatal genetic testing. The company aimed to expand its services in preimplantation genetic screening and non-invasive prenatal testing.

 Request a free sample copy or view report summary: Preimplantation Genetic Testing Market Report

Preimplantation Genetic Testing Market Report Highlights

• The reagents and consumables segment dominated the preimplantation genetic testing market and contributed 50.0% of the market share in 2024. In 2024, the instruments segment held the second-largest share of the preimplantation genetic testing industry.

• The Polymerase Chain Reaction (PCR) segment dominated the preimplantation genetic testing industry and contributed 39.6% to the market share in 2024. Next-generation sequencing (NGS) is projected to grow at the fastest CAGR during the forecast period.

• The aneuploidy screening segment dominated in 2024 and contributed 26.0% of the market share. In 2024, the HLA typing segment accounted for the second-largest market share.

• In 2024, the hospital segment captured the largest revenue share, accounting for approximately 39.3%. Fertility centers are expected to emerge as the most lucrative of all over the forecast period.

• The Europe preimplantation genetic testing market dominated the global market in 2024, capturing the largest revenue share at 34.65%. Asia Pacific preimplantation genetic testing industry is anticipated to witness the fastest CAGR of 7.4% over the forecast period.

Preimplantation Genetic Testing Market Segmentation

Grand View Research has segmented global preimplantation genetic testing market report based on procedure, product, technology, application, end-use, and region:

Preimplantation Genetic Testing Procedure Outlook (Revenue, USD Million, 2018 - 2030)

• Preimplantation Genetic Screening

• Preimplantation Genetic Diagnosis

Preimplantation Genetic Testing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents and Consumables

• Instruments

• Software

Preimplantation Genetic Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Next Generation Sequencing (NGS)

• Polymerase Chain Reaction (PCR)

• Fluorescent In-Situ Hybridization (FISH)

• Others

Preimplantation Genetic Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Chromosomal Abnormalities

• X-linked Diseases

• Embryo Testing

• Aneuploidy Screening

• HLA Typing

• Other Applications

Preimplantation Genetic Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Fertility Centers

• Hospitals

• Diagnostic Centers

• Research Centers and Academic Labs

Preimplantation Genetic Testing Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Preimplantation Genetic Testing Market

• Quest Diagnostics Incorporated

• Natera, Inc.

• COOPER SURGICAL, INC.

• Genea Pty Limited.

• Invitae Corporation

• Laboratory Corporation of America Holdings

• Thermo Fisher Scientific Inc.

• Bioarray S.L.

• Illumina, Inc.

• Igenomix

• RGI

• F. Hoffmann-La Roche Ltd